PTGS2 and colorectal carcinoma: As proof of concept, addition of a COX2 inhibitor produced a consistent, synergistic increase in sensitivity to vemurafenib across a panel of BRAFV600E CRC cell lines, which was not recapitulated in BRAFV600E melanoma (Fig. 6a).